Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.88, for a total value of $131,736.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $56.45 on Thursday. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $45.70 and a 200 day moving average of $36.48. The firm has a market capitalization of $5.91 billion, a price-to-earnings ratio of 44.80 and a beta of 0.45. Corcept Therapeutics Incorporated has a 52 week low of $20.84 and a 52 week high of $61.66.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. During the same period in the prior year, the firm earned $0.28 earnings per share. Corcept Therapeutics’s revenue was up 47.7% on a year-over-year basis. As a group, research analysts expect that Corcept Therapeutics Incorporated will post 1.31 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Truist Financial increased their target price on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a report on Monday, September 30th. Canaccord Genuity Group restated a “buy” rating and set a $38.00 target price on shares of Corcept Therapeutics in a report on Tuesday, July 30th. StockNews.com raised Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 31st. Piper Sandler increased their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, September 18th. Finally, Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $65.25.

Hedge Funds Weigh In On Corcept Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Hancock Whitney Corp lifted its holdings in shares of Corcept Therapeutics by 1.2% during the third quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company’s stock valued at $1,062,000 after purchasing an additional 270 shares during the last quarter. KBC Group NV boosted its holdings in Corcept Therapeutics by 21.3% in the third quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 496 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Corcept Therapeutics by 10.5% in the second quarter. Nisa Investment Advisors LLC now owns 5,368 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 510 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Corcept Therapeutics in the third quarter worth $25,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Corcept Therapeutics by 0.4% during the second quarter. Allspring Global Investments Holdings LLC now owns 127,348 shares of the biotechnology company’s stock valued at $4,138,000 after acquiring an additional 541 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.